Poland - Miscellaneous medicinal products

For more information and to make a bid you will need to go to the third party website.

Details

Provided by Open Opps
Opportunity closing date
06 August 2020
Opportunity publication date
06 July 2020
Category
33690000: Va
Value of contract
to be confirmed
Your guide to exporting
Report opportunity

Description

Purchase and supply of medicines used within the framework of drug programmes for the needs of Radom Specialist Hospital.
Beta interferon 1-b - 450 op.Cd. from section VI.3:c) declaration of the economic operator on the absence of a ruling against him/her as a preventive measure of the ban on public procurement; d) an extract from the relevant register or from the central register and information on business activity, if separate regulations require an entry in the register or register, in order to confirm the absence of grounds for exclusion under art. 24 par. 5 item 1 of the PPL Act; e) if the economic operator has its seat or place of residence outside the territory of the Republic of Poland, instead of the documents referred to in:1) letter A) of the Act on Public Procurement; f) a declaration of the economic operator on the absence of grounds for exclusion under art. 24 par. 5 item 1 of the PPL Act. a - shall submit information from a relevant register or, in the absence of such a register, another equivalent document issued by a competent judicial or administrative authority of the country where the economic operator has its registered office or place of residence or the person to whom the information or document relates, within the scope specified in Article 24(1)(13), (14) and (21) of the PPL Act;2) letter d - shall submit a document or documents issued in the country where the economic operator has its registered office or place of residence, confirming that no liquidation has been opened or bankruptcy declared.3) The documents referred to in points 1 and 2 should be issued not earlier than 6 months before the deadline for submission of tenders.4) If in the country where the economic operator has its seat or place of residence or the person to whom the document relates is not issued, the documents referred to in item 1 shall be replaced by a document containing, respectively, a statement by the economic operator, indicating the person or persons authorised to represent him or a statement by the person to whom the document was to refer, made before a notary public or before a judicial, administrative or professional or economic self-government body competent in respect of the economic operator's seat or place of residence or the place of residence of that person.5) The economic operator having its registered office in the territory of the Republic of Poland, with reference to a person having a place of residence outside the territory of the Republic of Poland to which the document indicated in item a relates, shall submit the document referred to in item 1 within the scope defined in art. 24 item 1 points 14 and 21 of the PPL Act. If in the country in which the person to whom the document was to apply is domiciled, such documents are not issued, they shall be replaced by a document containing a statement by that person submitted before a notary public or before a judicial, administrative or professional or economic self-government body competent for the place of residence of that person.6.5.3. List of declarations or documents submitted by the contractor in the proceedings at the request of the contracting authority to confirm the circumstances referred to in art. 25 par. 1 item 2 of the PPL Act:a) contractor's statement that the medicinal products offered by the contractor have the permit of the Minister of Health or the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products or the Council of the European Union or the European Commission for the authorization of the medicinal product to be marketed.8.1 The condition for participation in the proceedings is the payment of a deposit.8 part no. 13 - 140 PLN; part no. 14 - 318 PLN; part no. 15 - 244 PLN; part no. 16 - 40 PLN; part no. 17 - 2 083 PLN; part no. 18 - 1 323 PLN; part no. 19 - 3 472 PLN; part no. 20 - 52 PLN; part no. 21 - 222 PLN; part no. 22 - 1 597 PLN; part no. 23 - 464 PLN; part no. 24 - 944 PLN; part no. 25 - 2 313 PLN. The numbering is consistent with the numbering in the ToR. Interferon beta 1-a inj. - 45 op. Beta 1-a - 120 op. Glatirameri acetas - 50 op. Dimethylis fumaras - 255 op. Fingolimod - 85 Op. Alemtuzumab - 5 vials. Natalizumab - 24 vials. Teriflunomide - 135 op. Ocrelizumabum - 8 vials. Cladribinum - 14 tabl. Rybavirin - 1 400 tabl. /cap. Entecavir - 375 op. Adefovir - 35 Op. Tenofovirum disoproxilum - 230 op. Lamivudine - 45 op. Elbaswir + grazoprewir - 30 op. Sofosbuvir + velpatasvir - 3 op. Glecaprevir + pibrentasvir - 30 op. Bicalutamid - 300 op. Paricalcitol - 700 vials. Cinacalcet - 750 000 mg Aflibercept - 30 vials. Ranibizumab - 60 vials. Palivizumab - 100 pcs.

Opportunity closing date
06 August 2020
Value of contract
to be confirmed

About the buyer

Address
Radomski Szpital Specjalistyczny im. dr. Tytusa Chałubińskiego ul. Lekarska 4 Radom 26-610 Poland
Contact
zampubl@rszs.regiony.pl

The deadline to apply for this opportunity has passed.
Visit the opportunities page to find another.

Is there anything wrong with this page?